Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults with Uncomplicated Influenza

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 11 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Masiloxavir (Primary)
Indications Influenza virus infections
Focus Registrational; Therapeutic Use
Sponsors Nanjing Zenshine Pharmaceuticals

Most Recent Events

01 Feb 2025 Primary endpoint has been met. (The time to the remission of all influenza symptoms (hours)), according to a results published in the Clinical Microbiology and Infection.
01 Feb 2025 Results published in the Clinical Microbiology and Infection.
05 Nov 2024 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com